A Pilot Study on Proteomic Predictors of Mortality in Stable COPD
Proteomic predictors of mortality in COPD and their connection to respiratory, cardiovascular, and cancer-related deaths
Can Proteomic Predictors of Mortality Help Forecast Outcomes in Stable COPD?
Most of the long-term deaths are attributable to respiratory causes, with lower percentages attributed to cardiovascular/cerebrovascular events or cancer.
It is worth nothing that a trend toward better prognoses (disease progression, exacerbations, and mortality) has been observed in the last few years.
This phenomenon may be due to recent changes in treatment and involves the need for new studies on the current predictors of mortality.
Studying proteomic predictors of mortality in COPD to improve survival prognosis
Therefore, the objective of this pilot study was to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality, identifying the related pathways and contributing to our knowledge on the mechanisms linked to a poor prognosis for COPD patients.
Proteomic predictors of mortality in COPD: Understanding the biological mechanisms involved in future deaths in long-term patients
A proteomic blood signature found in stable COPD patients can help in establishing their long-term (4-year) survival prognosis.
The most important elements for establishing this prognosis are proteins/peptides linked to the hemostatic and inflammatory statuses during the stable phase, as well as different elements of the immune response.
Furthermore, the present results may help us to better understand the biological mechanisms involved in future deaths in long-term patients.
Authors
Cesar Jessé Enríquez-Rodríguez, Carme Casadevall, Rosa Faner, Sergi Pascual-Guardia, Ady Castro-Acosta, José Luis López-Campos, Germán Peces-Barba, Luis Seijo, Oswaldo Antonio Caguana-Vélez, Eduard Monsó, Diego Rodríguez-Chiaradia, Esther Barreiro, Borja G. Cosío, Alvar Agustí, Joaquim Gea and on behalf of the BIOMEPOC Group
Read more details at
Fecha de publicación
Published: 14 August 2024
Categorías asociadas al artículo
Noticias relacionadas
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
Treatable Traits. Why, What, How?
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Cellular Senescence Markers and Matrix Metalloproteinase-7 Are Co-expressed in Fibrosing Interstitial Lung Diseases
Study highlights the role of cellular senescence markers (p16, p21) and MMP-7 co-expression in fibrosing interstitial lung diseases.
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Different Immune Infiltrate in Idiopathic Pulmonary Fibrosis Patients With Stable and Progressive Disease
Research on idiopathic pulmonary fibrosis reveals how immune infiltrate differences in early stages influence disease progression. Study highlights the role of B cells, T cells, and NK cells as potential biomarkers.
Imagen desarrollada DALL·E, Canva y Diseño gráfico